At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 252 enrolled
Drug / intervention
Bioseal Fibrin Sealant +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Manual Compression as an Adjunct to Hemostasis in the Patients Undergoing Elective Vascular Surgery
In Brief
A Phase 4 clinical trial evaluating Bioseal Fibrin Sealant and Manual Compression for Cardiovascular Bleeding and 2 related conditions. Completed, enrolled 252 participants across 9 sites.
Detailed Summary
To evaluate the clinical utility of Bioseal as an adjunct to control bleeding during elective vascular surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Bleeding, Vascular Bleeding, Hemorrhage
CountriesChina
CollaboratorsGuangzhou Bioseal Biotechnology Co., Ltd.
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2014
First PostedMar 2014
Primary CompletionNov 2014
Study CompletionDec 2014
TodayJul 2026
First PostedMar 24, 2014
Enrollment StartFeb 1, 2014
Primary CompletionNov 1, 2014
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.3 years ago
Interventions
Bioseal Fibrin Sealantbiological
Manual Compressionother